Page last updated: 2024-12-10

glycyl-prolyl-glutamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycyl-prolyl-glutamic acid: N-terminal cleavage product of IGF-1; has neuroprotective activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3080768
CHEMBL ID371315
CHEBI ID163960
SCHEMBL ID1170125
MeSH IDM0171895

Synonyms (23)

Synonym
l-glutamic acid, n-(1-glycyl-l-prolyl)-
unii-zyk4rvv5ls
zyk4rvv5ls ,
glycyl-prolyl-glutamic acid
GPE ,
CHEBI:163960
(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid
32302-76-4
gly-pro-glu
CHEMBL371315
SCHEMBL1170125
DTXSID80186038
gly-pro-glu, >=98% (hplc)
l-glutamic acid, glycyl-l-prolyl-
(1-3)-human insulin-like growth factor i
glypromate
(1-3)igf-1
mfcd00144405
igf-i (1-3)
glycyl-l-prolyl-l-glutamic acid
DB05633
CS-0066182
HY-117483

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic studies were conducted in adult rats using a single bolus intravenous injection of GPE at 30 or 100 mg/kg and showed that GPE was rapidly cleared from the circulation."( Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats.
Batchelor, DC; Breier, BH; Gluckman, PD; Keven, C; Lin, H; Thomas, GB; Van Zijl, PL; Wen, JY, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
" NNZ-2566 is a structural analogue of Glypromate, resulting from alpha-methylation of the proline moiety, which has improved the elimination half-life and oral bioavailability over the parent peptide."( NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.
Batchelor, DC; Bickerdike, MJ; Brimble, MA; Gluckman, PD; Harris, PW; Leong, W; Lin, H; Sieg, F; Sirimanne, ES; Thomas, GB; Wen, J, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" In the initial dose-response experiments, NNZ-2566 (0."( NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury.
Chen, RW; Dave, JR; Liao, Z; Lu, XC; Tortella, FC; Wei, H; Yang, X; Yao, C, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID239119Displacement of L-[3H]glutamate from N-methyl-D-aspartate glutamate receptor in rat brain synaptic membranes2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Analogues of the neuroprotective tripeptide Gly-Pro-Glu (GPE): synthesis and structure-activity relationships.
AID1574163Neuroprotective activity against Abeta (25 to 35 residues)-induced cell death in human THP1 cells assessed as cell survival at 10 uM preincubated for 2 hrs followed by Abeta (25 to 35 residues) addition and measured after 24 hrs by MTT assay (Rvb = 40%)2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents.
AID1574174Antiinflammatory activity in human THP1 cells assessed as reduction in Abeta (25 to 35 residues)-induced TNFalpha expression at 10 uM preincubated for 2 hrs followed by Abeta (25 to 35 residues) addition and measured after 24 hrs by Trizol reagent based R2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents.
AID262014Displacement of L-[3H]glutamate from glutamate receptor in rat brain synaptic membrane2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity.
AID267563Displacement of L[3H]glutamate from GluR in rat brain synaptic membrane2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity.
AID1574161Half life in human plasma2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents.
AID1574164Neuroprotective activity against H2O2-induced cell death in human THP1 cells assessed as cell survival at 10 uM preincubated for 2 hrs followed by H2O2 addition and measured after 24 hrs by MTT assay (Rvb = 43%)2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents.
AID1574173Antiinflammatory activity in human THP1 cells assessed as reduction in LPS-induced TNFalpha expression at 10 uM preincubated for 2 hrs followed by LPS addition and measured after 24 hrs by Trizol reagent based RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.33)18.7374
1990's5 (11.63)18.2507
2000's24 (55.81)29.6817
2010's9 (20.93)24.3611
2020's4 (9.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.55 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (11.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (88.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]